Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review

Rachaneni, Suneetha; Arya, Pratibha; Latthe, Pallavi

doi:10.1007/s00192-013-2104-0

Cited by 26 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGF and ATP are representative and useful urinary biomarkers for OAB. 13,14 These factors are produced from bladder smooth muscle and urothelium. In fact, anticholinergic drugs for OAB reduce their urinary levels, which are produced from these tissues.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T‐lymphotropic virus type 1‐associated myelopathy/tropical spastic paraparesis

et al. 2017

View full text Add to dashboard Cite

Objectives: To evaluate oral prosultiamine treatment in patients with overactive bladder accompanied by human T-lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis.Methods: This was a prospective, single-center, open-label study. Patients received oral prosultiamine (300 mg) once daily in the morning, and the overactive bladder symptom score and urine levels of overactive bladder-related biomarkers (nerve growth factor/creatinine and adenosine triphosphate/creatinine) 12 weeks after the initial administration were compared with the baseline values. In addition, the urodynamic parameters, including involuntary detrusor contraction and detrusor sphincter dyssynergia, were evaluated before and after treatment. Results: A total of 16 patients were recruited for this clinical study. In the overactive bladder symptom score, night-time frequency, urgency and the total score improved after oral prosultiamine treatment (P = 0.028, 0.001 and 0.004, respectively). Both urinary nerve growth factor/creatinine and adenosine triphosphate/creatinine levels decreased significantly after the treatment (P = 0.004 and 0.017, respectively). Urodynamic studies showed that the maximum cystometric capacity increased significantly after the treatment. However, the symptoms disappeared because of the treatment in six of 10 patients with involuntary detrusor contraction (60%) and three of seven patients with detrusor sphincter dyssynergia (42.9%). There were no serious adverse events. Conclusions: The changes in urodynamic parameters and urine levels of overactive bladder-related markers suggest that oral prosultiamine is a safe and effective treatment for overactive bladder with human T-lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…13,14 Several investigators have reported that anticholinergic drug treatment for non-neurogenic OAB reduced the levels of these OAB-related urinary biomarkers. 15,16 However, relationships between LUT dysfunction, including OAB symptoms as a result of HAM/ TSP, and these urinary biomarkers are still not reported.…”

mentioning

confidence: 99%

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T‐lymphotropic virus type 1‐associated myelopathy/tropical spastic paraparesis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…To overcome this problem, a biomarker is needed to differentiate between the two diseases. Rachaneni et al [37] discussed whether urinary NGF could serve as a biomarker of detrusor overactivity (DO) in patients with OAB. DO, which is defined as detrusor contractions during urodynamics, is responsible for symptoms in most OAB patients.…”

Section: Discussionmentioning

confidence: 99%

Urinary Nerve Growth Factor Could Be a Biomarker for Interstitial Cystitis/Painful Bladder Syndrome: A Meta-Analysis

Zhang

Yan³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

To examine whether urinary nerve growth factor (NGF) could serve as a biomarker for interstitial cystitis/painful bladder syndrome (IC/PBS), we conducted a comprehensive meta-analysis of 9 studies. Among the studies considered, patients with IC/PBS had higher urinary NGF and NGF/Cr levels compared to those of healthy people (SMD = 1.94, 95%CI = 0.79–3.08, P = 0.0009 and SMD = 1.79, 95%CI = 0.65–2.93, P = 0.002, respectively). In addition, there was a significant difference between patients with IC/PBS and patients with overactive bladder (OAB) symptoms with respect to the urinary NGF and NGF/Cr levels (SMD = −0.62, 95%CI = −1.00–−0.24, P = 0.001 and SMD = −0.70, 95%CI = −1.01–−0.39, P<0.0001, respectively). Furthermore, patients had a significantly lower urinary NGF level after successful treatment (SMD = 1.74, 95%CI = 0.32–3.17, P = 0.02). In conclusion, urinary NGF could be a useful biomarker for the diagnosis of OAB, a urinary biomarker for the differential diagnosis of IC/PBS and OAB (when a critical urinary NGF or NGF/Cr level is needed), and a predictive biomarker to help guide treatment.

show abstract

“…Near infrared spectroscopy has also been shown to be an unreliable method for detecting DO in women with OAB symptoms [31]. While several small studies have demonstrated a trend towards higher urinary nerve growth factor (NGF) in patients with DO, a recent systematic review of the literature has stated that the data are imprecise and hence NGF cannot be recommended for use in current clinical practice [32].…”

Section: Commentmentioning

confidence: 99%

Can we predict detrusor overactivity in women with lower urinary tract symptoms? The King's Detrusor Overactivity Score (KiDOS)

Giarenis

Musonda

Mastoroudes

et al. 2016

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

A prediction model is able to predict detrusor overactivity more accurately than a symptomatic diagnosis alone, in women with lower urinary tract symptoms. Abstract ObjectiveTraditionally, urodynamic studies (UDS) have been used to assess lower urinary tract symptoms (LUTS), but their routine use is now discouraged. While urodynamic stress incontinence is strongly associated with the symptom of stress urinary incontinence (SUI) and a positive cough test, there is a weak relationship between symptoms of overactive bladder and detrusor overactivity (DO). The aim of our study was to develop a model to predict DO in women with LUTS. Study DesignThis prospective study included consecutive women with LUTS attending a urodynamic clinic. All women underwent a comprehensive clinical and urodynamic assessment. The effect of each variable on the odds of DO was estimated both by univariate analysis and adjusted analysis using logistic regression. Results1006 women with LUTS were included in the study with 374 patients (37%) diagnosed with DO. The factors considered to be the best predictors of DO were urgency urinary incontinence, urge rating/void and parity (p-value <0.01). The absence of SUI, vaginal Page 3 of 26 A c c e p t e d M a n u s c r i p t 3 bulging and previous continence surgery were also good predictors of DO (p-value < 0.01).We have created a prediction model for DO based on our best predictors. In our scoring system, presence of UUI scores 5; mean urge rating/void ≥ 3 scores 3; parity ≥ 2 scores 2; previous continence surgery scores -1; presence of SUI scores -1; and the complaint of vaginal bulging scores -1. If a criterion is absent, then the score is 0 and the total score can vary from a value of -3 to +10. The Receiver Operating Characteristic (ROC) analysis for the overall cut-off points revealed an area under the curve of 0.748 (95%CI 0.741, 0.755). ConclusionThis model is able to predict DO more accurately than a symptomatic diagnosis alone, in women with LUTS. The introduction of this scoring system as a screening tool into clinical practice may reduce the need for expensive and invasive tests to diagnose DO, but cannot replace UDS completely.

show abstract

Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review

Cited by 26 publications

References 19 publications

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T‐lymphotropic virus type 1‐associated myelopathy/tropical spastic paraparesis

Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T‐lymphotropic virus type 1‐associated myelopathy/tropical spastic paraparesis

Urinary Nerve Growth Factor Could Be a Biomarker for Interstitial Cystitis/Painful Bladder Syndrome: A Meta-Analysis

Can we predict detrusor overactivity in women with lower urinary tract symptoms? The King's Detrusor Overactivity Score (KiDOS)

Contact Info

Product

Resources

About